Executive Director, Computational Biology Cardiovascular Renal Metabolic

Executive Director, Computational Biology – Cardio-Renal-Metabolic (CRM) Diseases

The Executive Director, Computational Biology – Cardio-Renal-Metabolic (CRM) Diseases is a scientific leader responsible for developing and delivering computational biology strategies for kidney research while contributing expertise across the broader CRM portfolio. As part of Computational Innovation in Ridgefield (RDG), the Executive Director will serve as the primary computational biology contact for the local CRM Therapeutic Area and as a key partner to Research, Experimental Medicine, Clinical Pharmacology and Safety.

The Executive Director will work in close collaboration with the Global Computational Biology CRM Head and teams to align priorities, share expertise, and enable coordinated delivery across the portfolio.

The Executive Director will guide the integration of human genetics, multi-omics, advanced analytics, AI-enabled methods, and translational data to identify and validate therapeutic opportunities, support indication and patient-segmentation strategies, identify biomarkers, and use computational evidence to inform project decisions from target discovery through proof of concept. The role is accountable for high-quality scientific delivery, effective collaboration, capability development, and computational insights that advance medicines for patients with kidney and related cardio-renal-metabolic diseases.

As a member of the Computational Innovation (CI) Ridgefield leadership team, the Executive Director will help shape site strategy, represent the Computational Biology CRM function, ensure operational excellence across CI functions, and foster a culture of high performance, and Innovation Unit wide collaboration. The Executive Director will strengthen the visibility and impact of Computational Innovation at the Ridgefield site and represent the organization externally through strategic academic and industry partnerships across the United States.

As an employee of Boehringer Ingelheim, you will actively contribute to the discovery, development, and delivery of our products to our patients and customers. Our global presence provides an opportunity for all employees to collaborate internationally, offering visibility and the opportunity to directly contribute to the company's success. We realize that our strength and competitive advantage lie with our people. We support our employees in several ways to foster a healthy working environment, meaningful work, mobility, networking, and work-life balance.

Our competitive compensation and benefit programs reflect Boehringer Ingelheim's high regard for our employees.

Strategy and Portfolio Contribution

• Develop and implement computational biology strategies for kidney research, aligned with the CRM therapeutic strategy and the broader Computational Innovation strategy.

• Serve as a strategic and scientific partner to therapeutic-area leaders, translating computational evidence into clear recommendations for program and portfolio decisions.

• Provide computational biology leadership from target discovery through clinical proof of concept, ensuring portfolio impact with analyses are timely, rigorous, reproducible, and aligned to the program needs.

• Contribute to disease-area and asset strategies across Kidney and the wider CRM portfolio, identifying connections across renal, cardiovascular, metabolic, and related disease biology.

• Prioritize activities and resources for assigned programs and initiatives, with clear deliverables and measures of impact.

Scientific and Data Strategy

• Integrate human genetics, single-cell and spatial data, multi-omics, real-world data, clinical data, quantitative disease biology, and AI/ML to…